Rhys D.O. Jones

1.6k citations

32 papers · 925 indexed · h-index 14

Impact in

Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism
- Antibiotics Pharmacokinetics and Efficacy
- Drug-Induced Hepatotoxicity and Protection
Computational Theory and Mathematics top 2%
- Computational Drug Discovery Methods

Papers in

Pharmacology 14
- Pharmacogenetics and Drug Metabolism 14
Statistics and Probability 5
- Statistical Methods in Clinical Trials 5

Co-authors: Handan He James Yates Christopher R. Gibson M. Sherry Ku Vikash K. Sinha Kimberly K. Adkison Thierry Lavé Volker Fischer
Journals: Journal of Pharmaceutical Sciences (7 papers)Clinical Cancer Research (2 papers)Drug Discovery Today (2 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)CPT Pharmacometrics & Systems Pharmacology (2 papers)
Partner nations: United Kingdom United States Singapore

In The Last Decade

Rhys D.O. Jones

29 papers receiving 894 citations

Peers

Countries citing papers authored by Rhys D.O. Jones

Since Specialization

Citations

This map shows the geographic impact of Rhys D.O. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rhys D.O. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rhys D.O. Jones more than expected).

Fields of papers citing papers by Rhys D.O. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rhys D.O. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rhys D.O. Jones. The network helps show where Rhys D.O. Jones may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Rhys D.O. Jones, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rhys D.O. Jones Line = papers co-authored together Rhys D.O. Jones links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Simulations probe the role of space in the interplay between drug-sensitive and drug-resistant cancer cells Journal of Theoretical Biology ·William A. Bliven, Rhys D.O. Jones, Gibin Powathil, Vanessa Szamberlan	2025	1
2	Evaluation of leptin treatment on maintenance of body weight loss in diet‐induced obese mice Diabetes Obesity and Metabolism ·Danna M. Breen, В Б Алексеев, W.E. Mason, Jimmy Kong, 彭成龙, J. Brent Kuzmiski, John C. Stansfield, Rhys D.O. Jones, Kendra K. Bence, V. Margaret Jackson	2025	0
3	Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio Drug Discovery Today ·Rasmus Jansson‐Löfmark, Markus Fridén, Lassina Badolo, Christine Ahlström, Ian Gurrell, Menelas N. Pangalos, Rhys D.O. Jones	2025	0
4	Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression CPT Pharmacometrics & Systems Pharmacology ·Л.А. Торопов, Theresa A. Proia, Thomas E. Parton, Lauren Beatty, Matthew Sung, Srinivas Mamidi, Y. M. Zigmantovich, Matthew Griffin, Galli Matienzo C, Jelena Urosevic, Anton I. Rosenbaum, Jiaqi Yuan, Krishna Aluri, Diane Ramsden, Niresh Hariparsad, Rhys D.O. Jones, Jerome T. Mettetal	2024	7
5	A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models The AAPS Journal ·Boryana Koseva, mbarretto, Shenghua Wen, Graeme Scarfe, Justin Cidado, Corinne Reimer, Niresh Hariparsad, Rhys D.O. Jones, Lisa Drew, Dermot F. McGinnity, Л.А. Торопов	2023	1
6	Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model Molecular Cancer Therapeutics ·Rhys D.O. Jones, T. Urbonas, André F. Teixeira da Silva, Xiaozhen Wu, Helen Tomkinson, Alwin G. Schuller	2023	4
7	Interspecies evaluation of a physiologically based pharmacokinetic model to predict the biodistribution dynamics of dendritic nanoparticles PLoS ONE ·Л.А. Торопов, 勲大友, Rhys D.O. Jones, Niresh Hariparsad, Dermot F. McGinnity	2023	1
8	Comparison of Tumor Binding Across Tumor Types and Cell Lines to Support Free Drug Considerations for Oncology Drug Discovery Journal of Pharmaceutical Sciences ·Violeta Larralde, Sangwoo Ryu, Woodrow Burchett, Carl D. Davis, Rhys D.O. Jones, Sam Zhang, Nina Kazachek, George Chang, Li Di	2023	1
9	The Pharmacokinetic–Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST Clinical Cancer Research ·Venkatesh Pilla Reddy, Rana Anjum, Michael Grondine, Aaron Smith, Deepa Bhavsar, Evan Barry, Sylvie M. Guichard, Wenlin Shao, Jason G. Kettle, Faten M. A. Diab, Don Cummings, Rhys D.O. Jones	2020	9
10	Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades Trends in Pharmacological Sciences ·Michael Davies, Rhys D.O. Jones, Ken Grime, Rasmus Jansson‐Löfmark, Adrian J. Fretland, Susanne Winiwarter, Paul Morgan, Dermot F. McGinnity	2020	85
11	Evaluation of Prediction Accuracy for Volume of Distribution in Rat and Human Using In Vitro, In Vivo, PBPK and QSAR Methods Journal of Pharmaceutical Sciences ·K. Pondo J., David A. Tess, Woodrow Burchett, George Chang, Nathaniel A. Woody, Christopher Keefer, Christine C. Orozco, Jian Lin, Violeta Larralde, Shinji Yamazaki, Rhys D.O. Jones, Li Di	2020	20
12	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status Annals of Oncology ·Anuradha Jayaram, Karolina Nowakowska, Joaquı́n Mateo, Tomás Martín Hernández, Sandeep Kumar, H J Park, Daniel Nava Rodrigues, Ruth Riisnaes, A. Zukiwski, Stefan Proniuk, Alice Bexon, Solène Dealbera, Diletta Bianchini, Zafeiris Zafeiriou, Mller Hp, Nina Tunariu, Simon Pacey, Rhys D.O. Jones, Johann S. de Bono, G. Attard	2017	3
13	The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models Clinical Cancer Research ·Alwin G. Schuller, Evan Barry, Rhys D.O. Jones, Ryan E. Henry, Melanie M. Frigault, Garry Beran, Е.Л. Десятскова, Maureen M. Hattersley, Aaron Smith, Joanne Wilson, Stefano Cairo, Olivier Déas, Delphine Nicolle, Ammar Adam, Michael Zinda, Corinne Reimer, Stephen E. Fawell, Edwin Clark, Celina M. D’Cruz	2015	57
14	Model-based drug discovery: implementation and impact Drug Discovery Today ·Sandra A. G. Visser, J. L. Brito, Rhys D.O. Jones, Virna Schuck, Ann‐Charlotte Egnell, Sheila Annie Peters, So In Kim, James Yates, Rasmus Jansson‐Löfmark, Laura Elice de Souza Ferreira Miranda, Marie Cooke, Simon T. Barry, Andrew Hughes, Ulf Bredberg	2013	46
15	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution Journal of Pharmaceutical Sciences ·Rhys D.O. Jones, Hannah M. Jones, Malcolm Rowland, Christopher R. Gibson, James Yates, Jenny Y. Chien, Barbara J. Ring, Kimberly K. Adkison, M. Sherry Ku, Handan He, Ragini Vuppugalla, Punit Marathe, Volker Fischer, Sandeep Dutta, Vikash K. Sinha, Thorir D. Bjornsson, Thierry Lavé, Patrick Poulin	2011	104
16	PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach Journal of Pharmaceutical Sciences ·Patrick Poulin, Rhys D.O. Jones, Hannah M. Jones, Christopher R. Gibson, Malcolm Rowland, Jenny Y. Chien, Barbara J. Ring, Kimberly K. Adkison, M. Sherry Ku, Handan He, Ragini Vuppugalla, Punit Marathe, Volker Fischer, Sandeep Dutta, Vikash K. Sinha, Thorir D. Bjornsson, Thierry Lavé, James Yates	2011	132
17	PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach Journal of Pharmaceutical Sciences ·Ragini Vuppugalla, Punit Marathe, Handan He, Rhys D.O. Jones, James Yates, Hannah M. Jones, Christopher R. Gibson, Jenny Y. Chien, Barbara J. Ring, Kimberly K. Adkison, M. Sherry Ku, Volker Fischer, Sandeep Dutta, Vikash K. Sinha, Thorir D. Bjornsson, Thierry Lavé, Patrick Poulin	2011	49
18	Modulation of the Partition Coefficient between Octanol and Buffer at pH 7.4 and p Ka to Achieve the Optimum Balance of Blood Clearance and Volume of Distribution for a Series of Tetrahydropyran Histamine Type 3 Receptor Antagonists Drug Metabolism and Disposition ·José Ma Framis de Mena, Rhys D.O. Jones, Kevin Beaumont, Mark I. Kemp	2009	35
19	The discovery of long acting β2-adrenoreceptor agonists Bioorganic & Medicinal Chemistry Letters ·Alan D. Brown, Mark E. Bunnage, Paul A. Glossop, Kim James, Rhys D.O. Jones, English Baroque Solists, Russell A. Lewthwaite, Simon J. Mantell, Christelle Perros-Huguet, David A. Price, Mike Trevethick, Rob Webster	2007	29
20	The discovery of indole-derived long acting β2-adrenoceptor agonists for the treatment of asthma and COPD Bioorganic & Medicinal Chemistry Letters ·Alan D. Brown, Mark E. Bunnage, Paul A. Glossop, Mark Holbrook, Rhys D.O. Jones, English Baroque Solists, Russell A. Lewthwaite, Simon J. Mantell, Christelle Perros-Huguet, David Price, Rob Webster	2007	22

About Rhys D.O. Jones

Rhys D.O. Jones is a scholar working on Pharmacology, Statistics and Probability, Computational Theory and Mathematics, Hepatology and Gastroenterology, having authored 32 papers that have together received 925 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (14 papers), Computational Drug Discovery Methods (7 papers), Drug Transport and Resistance Mechanisms (6 papers), Statistical Methods in Clinical Trials (5 papers), Analytical Chemistry and Chromatography (4 papers), Liver physiology and pathology (3 papers), Receptor Mechanisms and Signaling (3 papers) and Cancer Mechanisms and Therapy (2 papers). The work is most often cited by research in Pharmacology (400 citations), Computational Theory and Mathematics (243 citations), Oncology (306 citations), Statistics and Probability (85 citations) and Spectroscopy (124 citations). Rhys D.O. Jones has collaborated with scholars based in United Kingdom, United States and Singapore. Frequent co-authors include Handan He, James Yates, Christopher R. Gibson, M. Sherry Ku, Vikash K. Sinha, Kimberly K. Adkison, Thierry Lavé, Volker Fischer, Barbara J. Ring and Thorir D. Bjornsson. Their work appears in journals such as Journal of Pharmaceutical Sciences, Clinical Cancer Research, Drug Discovery Today, Bioorganic & Medicinal Chemistry Letters and CPT Pharmacometrics & Systems Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact